Scientifically reviewed by Dr Stephan Hansberg
Is GHK-Cu legal? Topical vs injectable status (2026)
GHK-Cu legal status in the US, UK and Australia as of October 2026, separating topical cosmetic copper tripeptide-1 from injectable GHK-Cu, with the FDA's 2026 category changes, the TGA's enforcement priority and WADA status.
Key takeaways
- •GHK-Cu is legally two different things: a cosmetic ingredient (copper tripeptide-1) in skin products, and an unapproved medicine when injected or presented as treating a condition.
- •US: injectable GHK-Cu was placed in Category 2 in 2023 and its nominations were withdrawn in 2026; non-injectable GHK-Cu is in Category 1, with an FDA advisory committee review due before the end of February 2027.
- •UK: copper tripeptide-1 is used in cosmetics; any product presented as a medicine needs a marketing authorisation.
- •Australia: the TGA named GHK-Cu in its June 2026 unapproved peptide enforcement priority and says such products are not on the ARTG.
- •Sport: GHK-Cu is not named on the 2026 WADA List, but USADA says topical peptides that are prohibited are prohibited by any route, so athletes should check with their anti-doping agency.
The short answer
Topical cosmetic products containing GHK-Cu, listed on labels as copper tripeptide-1, are sold lawfully as cosmetics in the US, UK and Australia when they make cosmetic rather than medical claims. Injectable GHK-Cu is not an approved medicine in any of the three countries, and Australia named it in its 2026 crackdown on unapproved peptides.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. It has been studied in cell and animal models for collagen and extracellular matrix research, which is why it appears in skincare. Its legal status depends on route and presentation, not on the molecule alone.
GHK-Cu status at a glance (October 2026)
| Jurisdiction | Topical cosmetic use | Injectable or medicinal use | Most recent change |
|---|---|---|---|
| United States | Regulated as a cosmetic if it makes only cosmetic claims | Not FDA-approved; injectable GHK-Cu was Category 2 from Sep 2023, nominations withdrawn Apr 2026 | Non-injectable GHK-Cu back in Category 1 (May 2026); PCAC review due by end Feb 2027 |
| United Kingdom | Cosmetic ingredient (copper tripeptide-1) under cosmetics law | Not a licensed medicine; medicines law applies to medicinal presentation | MHRA enforcing against medicinal peptide claims, 2026 |
| Australia | Cosmetic products sold; therapeutic claims bring TGA rules into play | Unapproved therapeutic good; named in TGA enforcement priority | TGA priority Jun 2026; joint statement 19 Jun 2026 |
| Sport (WADA) | Not named; check Global DRO | Not named; S0 may apply to non-approved pharmacological use | 2027 List names peptides in general under S0 |
Topical cosmetic versus injectable: why the split matters
Across all three countries, the same principle applies: a product's legal category follows its intended use. A face serum containing copper tripeptide-1 with claims about the appearance of skin is a cosmetic. A vial or pen of GHK-Cu presented for injection, or any product claiming to treat a condition, falls under medicines law, and none of the three regulators has approved an injectable GHK-Cu medicine.
Copper tripeptide-1 is listed in the European Commission's CosIng cosmetic ingredient inventory with a skin conditioning function, which reflects its established cosmetic use.
United States
The FDA treats GHK-Cu differently by route. On 29 September 2023 it placed GHK-Cu for injectable routes of administration in 503A Category 2, citing a possible risk of immunogenicity from aggregation and peptide-related impurities. In April 2026 the injectable nominations were withdrawn, and injectable GHK-Cu now sits on the FDA's nominated but withdrawn list.
GHK-Cu for non-injectable routes was briefly removed from Category 1 on 22 April 2026 when nominations were withdrawn, then restored after one nominator clarified on 5 May 2026 that it had meant to withdraw only the injectable nomination. The FDA's list updated 14 May 2026 shows GHK-Cu (except for injectable routes) in Category 1, and the FDA says it will consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027.
GHK-Cu was not part of the July 2026 committee votes. Cosmetic skin products are regulated separately under the FD&C Act's cosmetic provisions, and the FDA classifies a product as a drug, a cosmetic or both according to its intended use and claims.
United Kingdom
Topical products containing copper tripeptide-1 are sold in the UK as cosmetics, which are regulated under UK cosmetics law rather than by the MHRA. GHK-Cu is not a controlled drug. Injectable GHK-Cu has no UK marketing authorisation, and under the Human Medicines Regulations 2012 a product presented as treating disease or used to modify physiological function is a medicine. The MHRA's 2026 statements on peptide clinics apply in the same way to GHK-Cu as to other peptides.
Australia
The TGA added unapproved peptide products to its compliance priorities on 10 June 2026 and, in its joint statement with the Chief Medical Officer on 19 June 2026, named products containing GHK-Cu alongside BPC-157, TB-500, retatrutide and CJC-1295. It has said that these unapproved peptide products are not included in the Australian Register of Therapeutic Goods and that importing, advertising or supplying them is unlawful.
Cosmetic skincare containing copper tripeptide-1 is sold in Australia, and cosmetics are not therapeutic goods unless they make therapeutic claims. Injectable or therapeutic GHK-Cu products are the target of the TGA's 2026 enforcement.
Sport
GHK-Cu is not named on the 2026 WADA Prohibited List. USADA's cosmetics guidance lists non-palmitoylated tripeptide-1 (GHK) among cosmetic peptides it does not consider prohibited, but it does not address the copper complex specifically, and it stresses that a prohibited peptide is prohibited whether used topically, orally or by injection. The 2027 List, in force from 1 January 2027, names peptides in general within S0, so athletes should check Global DRO or their national anti-doping agency before using any GHK-Cu product.
Where Celyfe fits
Celyfe supplies GHK-Cu only within two pre-filled 3 ml research pens: GLOW (GHK-Cu 75 mg, BPC-157 15 mg, TB-500 15 mg) and KLOW (the GLOW composition plus KPV 15 mg). Their certificates of analysis are being re-issued and will be listed in the Celyfe COA library when published. These are research pens, not cosmetics, and are not intended for application to skin or for injection.
Sources
Checked 8 October 2026:
- FDA: Bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026 (GHK-Cu category 1 note), fda.gov
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu injectable entry dated 29 Sep 2023; current page as of 22 Apr 2026), fda.gov
- FDA: Pharmacy Compounding Advisory Committee, meeting before end of February 2027, fda.gov
- FDA: Is it a cosmetic, a drug, or both? (or is it soap?), fda.gov
- European Commission CosIng inventory: copper tripeptide-1 (skin conditioning)
- TGA media releases: compliance focus on unapproved peptide products (10 Jun 2026); concerns regarding public health risks associated with unapproved peptide products (19 Jun 2026); TGA flexes its muscle against illegal peptides and steroids (Aug 2026), tga.gov.au
- USADA: Peptides and growth factors in cosmetics: are they banned?, usada.org
- WADA: Prohibited List 2026, wada-ama.org
Research use only
Celyfe supplies research peptides for laboratory and research use only. Nothing on this page is guidance on use in humans or animals. This is general information, not legal advice. Rules in all three countries changed several times in 2026, so check the regulator's current publications or speak to a qualified adviser before relying on anything here.
Regulation alerts
Get notified when the rules change
We email when FDA, MHRA, TGA or WADA status changes for the compounds we cover, with the source linked. No spam, unsubscribe at any time.